Celldex Therapeutics (NASDAQ:CLDX) Price Target Lowered to $36.00 at The Goldman Sachs Group
Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its target price cut by The Goldman Sachs Group from $42.00 to $36.00 in a report released on Monday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald reiterated an “overweight” […]
Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its target price cut by The Goldman Sachs Group from $42.00 to $36.00 in a report released on Monday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald reiterated an “overweight” […]
